Lisa A. Jackson, MD, MPH

“Group Health gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Group Health Research Institute Senior Investigator
Group Health Physician

Biography

Lisa A. Jackson is an internist and infectious disease epidemiologist who has spent the past 20 years conducting clinical and epidemiologic studies of vaccine safety and efficacy.

In addition to her role as a senior scientific investigator at Group Health Research Institute (GHRI), she is a research professor in the University of Washington (UW) Department of Epidemiology and an adjunct research professor in the UW Department of Medicine

 Dr. Jackson is the principal investigator (PI) at Group Health of the Vaccine Safety Datalink Project sponsored by the Centers for Disease Control and Prevention. She is also PI of the Vaccine and Treatment Evaluation Unit hosted by GHRI, one of eight such facilities nationwide that are sponsored by the National Institutes of Health.

Dr. Jackson has authored more than 140 peer-reviewed publications and 14 book chapters.  She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Advisory Committee.

Dr. Jackson received her medical degree from the University of Virginia School of Medicine, Charlottesville, and her master of public health degree from the University of Washington School of Public Health and Community Medicine.

Research interests and experience

  • Vaccines & Infectious Diseases

    Vaccine  safety; influenza vaccine effectiveness in the elderly; methodologic issues in  vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine  effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly;  epidemiology of E. coli bacteremia; epidemiology of community-acquired  pneumonia

 

Recent publications

Havers FP, Flannery B, Clippard JR, Gaglani M, Zimmerman RK, Jackson LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA, Eng HF, Lamerato L, Campbell AP, Fry AM.

Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-14 influenza season.

Clin Infect Dis. 2015 Jun 1;60(11):1677-80. doi: 10.1093/cid/civ146. Epub 2015 Feb 25. PubMed

Keitel WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR.

Safety and immunogenicity of a subvirion monovalent unadjuvanted inactivated influenza A/H3N2 variant (H3N2V) vaccine in healthy persons>/=18 years old.

J Infect Dis. 2015 Feb 3. pii: jiv056 [Epub ahead of print]. PubMed

Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, McLean HQ, Belongia EA, Gaglani M, Berman L, Foust A, Sessions W, Thaker SN, Spencer S, Fry AM.

Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015.

MMWR Morb Mortal Wkly Rep. 2015;64(1):10-5. PubMed

Stratton KG, Cook AJ, Jackson LA, Nelson JC.

Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring.

Stat Med. 2015 Mar 30;34(7):1117-33. doi: 10.1002/sim.6398. Epub 2014 Dec 15. PubMed

 

Vaccines & Infectious Diseases

Immune response to bird flu vaccine is boosted by adjuvants

Vaccine Treatment and Evaluation Unit tests real-world use to prepare for H7N9.

Read it in News and Events.

GHRI In the Media

Immune response to bird flu vaccine is boosted by adjuvants

Bird-flu vaccine needs a boost, Seattle researchers find

The Seattle Times, July 21, 2015